Acurx Pharmaceuticals (ACXP) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acurx Pharmaceuticals is the larger company by market cap ($7.1 million vs $6.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | TRAW |
|---|---|---|
| Share price | $1.27 | $0.4452 |
| Market cap | $7.06M | $6.84M |
| 1-day change | +1.60% | -7.31% |
| EPS (TTM) | $-2.67 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $3.27 |
| 52-week low | $1.23 | $0.43 |
| Distance from 52-week high | -84.09% | -86.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1238.58% | +124.62% |
| Average volume | 125.08K | 569.02K |
| Shares outstanding | 5.56M | 15.37M |
| Employees | 4 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ACXP vs TRAW FAQ
Which is bigger, Acurx Pharmaceuticals or Traws Pharma?
Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $7.06M compared with $6.84M for Traws Pharma (TRAW).
Are Acurx Pharmaceuticals and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.